• Zentalis outlined a regulatory path for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer, keeping an accelerated-approval strategy in place.
• Enrollment finished in DENALI Phase 2 Parts 2a and 2b; Part 2c continues to enroll to broaden the registration-intended dataset.
• DENALI Part 2 topline results will be presented in 1H 2027, timed to allow the trial’s data to mature.
• ASPENOVA Phase 3, a confirmatory study aimed at supporting full approval and ex-US filings, has dosed its first patient and is enrolling.
• Earlier results will be presented in the future at ESMO 2026, with an accepted rapid oral presentation on survival analysis from DENALI Part 1b.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001725160-26-000061), on August 06, 2026, and is solely responsible for the information contained therein.